Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Nivolumab +/- Ipilimumab for Advanced Gynecologic Cancers with Peritoneal Carcinomatosis
Recruiting1 awardPhase 1
Houston, Texas
This trial is studying the side effects and best dose of nivolumab with or without ipilimumab to treat patients with female reproductive cancer that has come back or is high grade and has spread extensively throughout the peritoneal cavity.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.